Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 4/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243178 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL20553048 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL20477154 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL29727834 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL17712276 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| Maleic Acid SCHEMBL20552110 | 0.94 | TMPRSS2 (0.36) | PDE2ATMPRSS2HSPA5PTPN1CDC25B | |
| SCHEMBL24158032 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL22646505 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL14817042 | 0.92 | HSPA5 (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL12393267 | 0.91 | PDE2A (0.35) | PDE2AHTR1AHSPA5PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-4319762-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Emory University (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022217153-A2 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | PDE2A 919/4885TMPRSS2 355/4885HTR1A 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.